The stock of Ventyx Biosciences Inc (NASDAQ: VTYX) has decreased by -1.79 when compared to last closing price of 2.23.Despite this, the company has seen a loss of -6.81% in its stock price over the last five trading days. globenewswire.com reported 2024-12-10 that NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ventyx Biosciences, Inc. (NASDAQ: VTYX) on behalf of long-term stockholders following a class action complaint that was filed against Ventyx on March 1, 2024 with a Class Period from October 21, 2021 to November 6, 2023. Our investigation concerns whether the board of directors of Ventyx have breached their fiduciary duties to the company.
Is It Worth Investing in Ventyx Biosciences Inc (NASDAQ: VTYX) Right Now?
VTYX has 36-month beta value of 0.53. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VTYX is 52.87M, and currently, short sellers hold a 16.33% ratio of that float. The average trading volume of VTYX on January 01, 2025 was 1.42M shares.
VTYX’s Market Performance
VTYX stock saw a decrease of -6.81% in the past week, with a monthly decline of -18.28% and a quarterly a decrease of 5.29%. The volatility ratio for the week is 6.88%, and the volatility levels for the last 30 days are 9.79% for Ventyx Biosciences Inc (VTYX). The simple moving average for the last 20 days is -10.59% for VTYX’s stock, with a simple moving average of -28.79% for the last 200 days.
Analysts’ Opinion of VTYX
Many brokerage firms have already submitted their reports for VTYX stocks, with Wells Fargo repeating the rating for VTYX by listing it as a “Overweight.” The predicted price for VTYX in the upcoming period, according to Wells Fargo is $16 based on the research report published on March 12, 2024 of the previous year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see VTYX reach a price target of $12. The rating they have provided for VTYX stocks is “Outperform” according to the report published on March 12th, 2024.
Wells Fargo gave a rating of “Equal Weight” to VTYX, setting the target price at $8 in the report published on November 07th of the previous year.
VTYX Trading at -3.90% from the 50-Day Moving Average
After a stumble in the market that brought VTYX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.92% of loss for the given period.
Volatility was left at 9.79%, however, over the last 30 days, the volatility rate increased by 6.88%, as shares sank -13.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.78% lower at present.
During the last 5 trading sessions, VTYX fell by -6.81%, which changed the moving average for the period of 200-days by -71.56% in comparison to the 20-day moving average, which settled at $2.45. In addition, Ventyx Biosciences Inc saw -11.34% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VTYX starting from Nuss John, who sale 21,119 shares at the price of $2.36 back on Dec 27 ’24. After this action, Nuss John now owns 464,582 shares of Ventyx Biosciences Inc, valued at $49,841 using the latest closing price.
Nuss John, the Officer of Ventyx Biosciences Inc, proposed sale 21,119 shares at $2.36 during a trade that took place back on Dec 27 ’24, which means that Nuss John is holding shares at $49,842 based on the most recent closing price.
Stock Fundamentals for VTYX
Current profitability levels for the company are sitting at:
- -152.58 for the present operating margin
- -0.05 for the gross margin
The net margin for Ventyx Biosciences Inc stands at -141.75. The total capital return value is set at -0.57. Equity return is now at value -54.24, with -48.98 for asset returns.
Currently, EBITDA for the company is -207.84 million with net debt to EBITDA at 0.31. When we switch over and look at the enterprise to sales, we see a ratio of 96.77. The liquidity ratio also appears to be rather interesting for investors as it stands at 23.52.
Conclusion
To put it simply, Ventyx Biosciences Inc (VTYX) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
